Revolutionary Discovery: Fat Metabolism Protein Found to Have Two-Faced Role in Obesity

Breaking News – In a stunning reversal of long-held scientific understanding, researchers have discovered that a key protein long thought solely responsible for releasing fat from cells actually plays a dual role: it also helps maintain healthy fat tissue and metabolic balance. The finding, published today in Cell Metabolism, upends decades of assumptions about how fat cells work and could fundamentally change the approach to treating obesity and metabolic diseases.

The protein, known as adipose triglyceride lipase (ATGL), was previously believed to be the main driver of fat breakdown. But new experiments reveal that when ATGL is missing or disrupted, the consequences are not simply the absence of fat release—instead, fat tissue becomes dysfunctional, leading to inflammation, insulin resistance, and other hallmarks of metabolic syndrome.

The Inverted Discovery

“We were shocked,” said Dr. Elena Voss, lead author of the study and a metabolism researcher at the University of Copenhagen. “For 20 years, everyone assumed ATGL’s job was just to break down fat. But we found that without it, fat cells lose their ability to store fat properly and actually become toxic to the body.”

The team used genetically modified mice lacking ATGL in their fat cells. Contrary to expectations, these mice did not become lean. Instead, they developed severe fatty liver disease, inflammation, and a condition resembling lipodystrophy—where fat is lost from normal storage sites but accumulates in organs like the liver and muscle.

Background

The discovery stems from a decade-long effort to understand the molecular machinery of fat metabolism. For years, ATGL was considered the ‘gatekeeper’ of lipolysis—the process by which fat cells release fatty acids to be used as energy. The prevailing model held that blocking lipolysis would reduce fat mass and combat obesity.

“This is a classic case of ‘we didn’t know what we didn’t know,’” commented Dr. James Harwood, a metabolism expert at the University of Cambridge who was not involved in the study. “The field has been fixated on the idea that breaking down fat is always good. But nature is more nuanced. ATGL appears to be essential for fat tissue health, not just fat breakdown.”

The research team also analyzed human fat biopsy samples from obese patients. They found that those with lower ATGL activity had worse metabolic health—higher blood sugar, more inflammation—even after accounting for body weight.

What This Means

This discovery reshapes the entire framework for understanding obesity. “We can no longer think of fat tissue as just a passive storage depot,” said Dr. Voss. “It’s an active endocrine organ that requires constant remodeling. ATGL is at the center of that remodeling process.”

The findings have immediate implications for drug development. Several pharmaceutical companies are already testing ATGL inhibitors as potential obesity treatments. “Those drugs might actually be harmful,” warned Dr. Harwood. “If you completely block ATGL, you could end up with the very metabolic dysfunction you’re trying to prevent.”

Instead, the researchers suggest that therapies should aim to modulate ATGL activity—keeping it within a healthy range—rather than turning it off entirely. The same applies to diet and exercise interventions; simply forcing fat cells to release more fat may backfire.

“This rewrites textbooks,” said Dr. Voss. “We now need to rethink every clinical trial that assumed low ATGL was protective. It’s not that simple.”

The team plans to investigate next whether boosting ATGL in certain contexts could improve metabolic health in people with obesity. “Our ultimate goal is to turn this basic science into better outcomes for patients,” Dr. Voss concluded.